INmune Bio and UK charity Anthony Nolan have expanded their collaboration to enhance the CORDStrom™ MSC platform, using high-quality umbilical cord tissue to develop consistent, scalable cell therapies. This partnership targets treatments for Recessive Dystrophic Epidermolysis Bullosa (RDEB), oncology, and inflammatory diseases like osteoarthritis and lupus. The agreement ensures regulatory compliance and quality standards, leveraging Anthony Nolan's expertise in stem cell sourcing. This strategic move aims to overcome previous challenges in MSC therapy consistency and advance new treatments toward commercial approval.
Alamar Biosciences announced that its NULISA platform was prominently featured in over 140 scientific presentations at the 2026 Alzheimer's Association International Conference (AAIC) in London, highlighting its growing adoption in Alzheimer's resear...
Alamar Biosciences presented extensive data from its NULISA platform at the AAIC 2026 conference, highlighting advances in blood-based biomarkers for Alzheimer's detection and staging. The company emphasized new findings on eMTBR-Tau and BD-pTau217, ...
Holtec Nuclear Corporation has filed a registration statement with the U.S. SEC for a proposed initial public offering (IPO) of its Class A common stock, planning to list on Nasdaq under the symbol "HNUC." The offering details, including share count ...
DeFi platform Aave introduced Stable Vaults, enabling fintechs and payment providers to offer fixed-rate stablecoin yields, enhancing its ecosystem. This launch, alongside the Aave V4 upgrade, increased token trading volume by 14.5% and price by near...
Morgan Stanley has filed to launch Ethereum and Solana ETFs with a competitive 0.14% management fee, aiming to capture market share as crypto ETFs become more commoditized. These ETFs will offer direct token exposure, staking rewards, and institution...
